SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

ClinicalTrials.gov ID: NCT01574274

Public ClinicalTrials.gov record NCT01574274. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Study of Intravenous Calaspargase Pegol (SC-PEG Asparaginase) and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Study identification

NCT ID: NCT01574274
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Dana-Farber Cancer Institute; Other
Enrollment: 240 participants

Conditions and interventions

Conditions

Interventions

SC-PEG Drug
Oncaspar Drug

Drug

Eligibility (public fields only)

Age range: 365 Days to 21 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2012
Primary completion: Jun 30, 2021
Completion: Jun 30, 2027
Last update posted: Feb 4, 2026

2012 – 2027

United States locations

U.S. sites: 5
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Children's Hospital Boston	Boston	Massachusetts	02215	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian	New York	New York	10032	—
Montefiore Medical Center	New York	New York	10467	—
Hasbro Children's Hospital	Providence	Rhode Island	02903	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01574274, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 4, 2026 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01574274 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →